Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 7/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 1.00 |
| ▸ | NNMT | P40261 | 5/20 | 1.00 |
| ▸ | CARM1 | Q86X55 | 5/20 | 1.00 |
| ▸ | SETD7 | Q8WTS6 | 4/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 3/20 | 1.00 |
| ▸ | PCMT1 | P22061 | 2/20 | 1.00 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 1.00 |
| ▸ | TRDMT1 | O14717 | 2/20 | 1.00 |
| ▸ | PRMT5 | O14744 | 2/20 | 1.00 |
| ▸ | INMT | O95050 | 2/20 | 1.00 |
| ▸ | METTL3 | Q86U44 | 2/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 1.00 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 1.00 |
| ▸ | RNMT | O43148 | 1/20 | 1.00 |
| ▸ | TPMT | P51580 | 1/20 | 1.00 |
| ▸ | NSD1 | Q96L73 | 1/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sinefungin SCHEMBL30779328 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL19421010 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL38665462 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL24478706 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL14174630 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL23607779 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL167609 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL3400839 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL20992057 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL19418813 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3823671-B1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FOND ASILE DES AVEUGLES (CH) | 2024-02-07 | — | — | EP | claimed |
| US-20210213013-A1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FONDATION ASILE DES AVEUGLES (CH) | 2021-07-15 | — | — | US | claimed |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | WISTAR INST (US) | 2025-01-09 | — | — | US | disclosed |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | The Wistar Institut of Anatomy and Biology (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3607084-B1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | UNIV WESTERN AUSTRALIA (AU) | 2024-05-01 | — | — | EP | disclosed |
| US-20210292807-A1 | METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2021-09-23 | — | — | US | disclosed |
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-08-19 | — | — | US | disclosed |
| US-10987353-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210023077-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2021-01-28 | — | — | US | disclosed |
| EP-3607084-A1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | The University Of Western Australia (AU) | 2020-02-12 | — | — | EP | disclosed |
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | NOVARTIS AG (CH) | 2019-11-19 | — | — | US | disclosed |
| EP-3227446-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Novartis AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| EP-3191592-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | Novartis AG (CH) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016089883-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016038550-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | NOVARTIS AG (CH) | 2016-03-17 | — | — | WO | disclosed |
| US-4914086-A | 9-DEAZAINOSINE | UNIVERSITY PATENTS, INC. | 1990-04-03 | — | — | US | disclosed |
| US-4158056-A | 5'-DEOXY-5'-(1,4-DIAMINO-4-CARBOXYBUTYL)ADENOSINE | ELI LILLY AND COMPANY (US) | 1979-06-12 | — | — | US | disclosed |
| US-4158056-A | 5'-DEOXY-5'-(1,4-DIAMINO-4-CARBOXYBUTYL)ADENOSINE | ELI LILLY AND COMPANY (US) | 1979-06-12 | — | — | US | disclosed |
| US-4087603-A | Antifungal antibiotics | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | PRMT5, PRMT1, PRMT3 | NSD2 225/4885DOT1L 45/4885NNMT 521/4885 |
| US-20210023077-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | NSD2 177/4885DOT1L 6/4885NNMT 158/4885 |
| US-10987353-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | CARM1, EZH2, PRMT1 | NSD2 175/4885DOT1L 8/4885NNMT 199/4885 |
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | NSD2 158/4885DOT1L 8/4885NNMT 188/4885 |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | NSD2 174/4885DOT1L 6/4885NNMT 156/4885 |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | PRMT5, PRMT1, PRMT3 | NSD2 225/4885DOT1L 45/4885NNMT 521/4885 |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | CARM1, EZH2, PRMT1 | NSD2 174/4885DOT1L 6/4885NNMT 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.